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Materials and Methods: From 8/2005 to 12/2007, 15 patients (pts),
25-61 years old, with high risk acute leukemias, underwent double
cord blood transplantation. HHV-6 reactivation was noticed in 7
(47%) at a median time of 40 days (range 25-127) post-transplant.
Myeloablative conditioning regimen was used in 5/7. Prophylac-
tic antiviral therapy consisted of acyclovir (n=5/7) or foscarnet
(n=2/7). Among them 2 pts had already CMV-infection and 6 (85.7%)
suffered from aGVHD and received methylprednisolone at the time
of HHV-6 reactivation. Levels of HHV-6 DNA in PBMCs and plasma
by RT-PCR were monitored every week. The viral load in PBMCs
ranged from 0.02 to 5.1 x 104 copies/ml (median 0.41 x 104).
Results: Clinical manifestations included fever, skin rash, throm-
botic microangiopathy, seizures, bone and joint pain, hemophago-
cytosis, persistent thrombocytopenia, and several concurrent in-
fections [bacterial (n=2): Pseudomonas putida, Staphylococcus
epidermidis, Rhizobium radiobacter/fungal (n=2): Aspergillus,
Acremonium/viral (n=4): CMV, EBV, BKV, RSV, Rhinovirus, Boca
virus/parasitic (n=1): toxoplasma gondii. Despite the fact that
the above manifestations could not always be attributed to HHV-
6, it seemed that their emergence and/or aggravation corre-
lated with its reactivation. Engraftment with ANC>microliter and
PLTs>50,000/microliter occurred at median time of 19 (range 6-
34) and 36 (range 41-95) days respectively. Two pts died before en-
graftment. Five pts received foscarnet and all but one responded
at a median time of 10 days (range 9-19). The non-responder re-
ceived cidofovir without response. In 3 pts, despite the reduction
of viral load, viral DNA had been detected for several weeks. With
a median follow up of 5 months (range 3-30), 3 pts died (systemic
toxoplasmosis at d+52, leucoencephalopathy and sepsis at d+93,
disease relapse at d+180).
Conclusions: A high incidence of HHV-6 reactivation with a variety
of manifestations was noticed, that may increase immunosuppres-
sion and predispose to infections, but no clear conclusion could
be made about its impact on engraftment. Further investigation is
needed to identify risk factors for HHV-6 reactivation, and optimal
prophylactic therapy.
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Introduction: Human bocavirus (HBoV) is a recently discovered
parvovirus frequently detected in respiratory samples from chil-
dren during winter. Its role in immunocompromised patients re-
mains unclear. We report a case of HBoV infection in a transplant
recipient.
Materials, Methods and Results: A 33-year-old woman with acute
lymphoblastic leukemia received an allogeneic hematopoietic stem
cell transplant in March 2007, from an unrelated, 9/10 HLA al-
leles matched, donor. On day+306, while in ongoing remission,
she presented with low grade fever, nasal congestion, neutrope-
nia and thrombocytopenia. During this period she had been receiv-
ing tacrolimus, mycophenolate mofetil and methylprednisolone for
persistent chronic GVHD. Anti-infective prophylaxis consisted of
penicillin, posaconazole, acyclovir, atovaquone. Nasopharyngeal
aspirates (NPA) were screened for 17 respiratory viruses (influenza
A, B, C, parainfluenza 1, 2, 3, 4a, 4b, RSV A, B, rinovirus, aden-
ovirus, echovirus, bocavirus, coronovirus, metapneumonovirus A,
B) with PCR/DNA microarrays on day+306. HBoV was the only pos-
itive virus. Concomitantly, CMV reactivation by PCR was identified
from blood. She was started on ganciclovir and one week later PCR
for CMV was negative. The neutrophil count normalized within 10
days but thrombocytopenia and rhinitis persisted and the patient' s
general health was not improved. On d+ 339 her temperature rose
to 39°C, dry cough and diarrhea ensued. d+ Chest radiograph and
CT showed mild pericardial effusion. The bronchoalveoral lavage
fluid was positive for HBoV without isolation of other pathogen.
NPA remained HBoV positive. Intestinal tissue biopsy was not di-
agnostic, but PCR analysis of the intestinal tissue was positive for
HBoV. On d+ 356 dyspnea and hypoxia were added. Chest radio-
graph showed diffuse infiltrations on both lungs. She died despite
respiratory support.
Conclusion: HBoV caused a persistent, disseminated and finally
fatal infection in that immunocompromised patient. Chronic GVHD
and immunosuppressive therapy probably predisposed to viral dis-
semination. Further investigation is required for estimation of
HBoV epidemiology and clinical manifestations in immunocompro-
mised patients.
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Background: Blood stream infections (BSI) remain an important
complication of HSCT. The aim of this study was to analyze etiol-
ogy, microbiological resistance and outcome of BSI after allogeneic
HSCT.
Materials: Retrospective review of BSI in patients treated at HSCT
Unit between 1/01/04 and 31/12/07.
Methods: BSI was defined as isolation of a pathogen from at least
one blood culture. For common skin contaminants, 2 consecutive
positive blood cultures were required. Survival after BSI was ana-
lyzed by univariate chi-square test.
Results: There were 169 episodes of BSI diagnosed in 132 patients
(median 10 days after HSCT, range: -47; 4876) and 183 pathogens
were isolated (Table 1).
Table 1. Etiology of 169 blood stream infections occurring between
01/01/04 and 31/12/07 in allogeneic stem cell transplant recipients
Organism Number (%)
Gram-positive 103 (56%)
Staphylococcus 45
Coagulase negative 41
Staphylococcus aureus 4
Enterococcus 40
Enterococcus faecalis 21
Enterococcus faecium 17
Others (E. avium, E. species) 2
Viridans streptococci 11
Corynebacterium 5
Others (Streptococcus pneumoniae, Rothia mucillaginosa) 2
Gram-negative 69 (38%)
Escherichia coli 25
Pseudomonas aeruginosa 20
Klebsiella pneumoniae 7
Enterobacter 7
Stenotrophomonas maltophilia 4
Burkholderia cepacia 3
Others (2 Pseudomonas species, 1 Acinetobacter species) 3
Candida 11 (6%)
krusei 4
albicans 2
parapsilosis 2
species 2
glabrata 1
